Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients

• Proportions of subjects in each group who achieve: HBV DNA < 300 copies/mL [ Time Frame: at week 48 ] [ Designated as safety issue: No ]
• Mean log10 reduction from baseline in HBVDNA [ Time Frame: at week 12, 24, 48 ] [ Designated as safety issue: No ]
• ALT normalization rate and range [ Time Frame: at week 12 and 48 ] [ Designated as safety issue: No ]
• Liver stiffness values reduction from baseline by Fibroscan [ Time Frame: at week 48 ] [ Designated as safety issue: No ]
• HBeAg loss and HBe seroconversion [ Time Frame: at week 12 and 48 ] [ Designated as safety issue: No ]
• HBsAg loss and HBs seroconversion [ Time Frame: at week 12 and 48 ] [ Designated as safety issue: No ]
• Improvement in symptoms score [ Time Frame: at week 12, 24 and 48 ] [ Designated as safety issue: No ]
• Frequency of adverse events [ Time Frame: up to 60 weeks ] [ Designated as safety issue: Yes ]
• Frequency of serious adverse events [ Time Frame: up to 60 weeks ] [ Designated as safety issue: Yes ]
• Frequency of discontinuations from study drug due to adverse events or laboratory abnormalities. [ Time Frame: up to 60 weeks ] [ Designated as safety issue: Yes ]

The purpose of the study is to evaluate the effects and safety of Adefovir Dipivoxil plus polyene phosphatidylcholine compared to Adefovir Dipivoxil alone in patients with chronic hepatitis B.

• Drug: Adefovir Dipivoxil and polyene phosphatidylcholine
  Adefovir Dipivoxil 10 mg once daily for 48 weeks plus Polyene phosphatidylcholine (PPC) 456 mg three times per day for 48 weeks
• Drug: Adefovir Dipivoxil
  Adefovir Dipivoxil 10 mg once daily for 48 weeks

• Experimental: Adefovir Dipivoxil and polyene phosphatidylcholine
  Adefovir Dipivoxil 10 mg once daily for 48 weeks plus Polyene phosphatidylcholine (PPC) 456 mg three times per day for 48 weeks
  Intervention: Drug: Adefovir Dipivoxil and polyene phosphatidylcholine
• Active Comparator: Adefovire Dipivoxil
  Adefovir Dipivoxil 10 mg once daily for 48 weeks
  Intervention: Drug: Adefovir Dipivoxil

Inclusion Criteria:

• Males and females between the age of 18 to 65 years with chronic hepatitis B.
• HBsAg positive for a minimum of 6 months.
• HBV DNA ≥4 log10 copies/ml, and ≤ 6 log10 copies/mL
• Alanine aminotransferase (ALT) ≥ 2 times the upper limit of normal(ULN) and ≤10 times ULN, and documented ALT abnormal within 6 month prior to the study screening.
• Had a liver biopsy performed within 6 months prior to randomization and has readable biopsy slides or agrees to have a biopsy performed prior to entry.
• Willing and able to provide written informed consent.

Exclusion Criteria:

• Received any nucleoside, nucleotide or interferon therapy within 6 months prior to the screening.
• Previous treatment with lamivudine, adefovir, entecavir or telbivudine and occurred viral breakthrough or genotype resistance.
• Received immunosuppressive agents or other immunoregulates (including thymosin),systemic cytotoxic drugs, other antiviral agents including Chinese herb medicine within 6 months prior to the screening.
• Active alcohol intake( more than 20g/d for female or more than 30g/d for male) or drug abuse within 1 year prior to screening. Alcohol or drug abuse considered by the investigator to be sufficient to hinder compliance with treatment, participation in the study or interpretation of results.
• ALT is greater than 10 times ULN at screening or has the history of transient decompensated liver disease due to acute exacerbation.

• Any of the laboratory test at screening as the following :

  • serum creatinine > 1.5 mg/dl ;
  • prothrombin time ≥ 4 seconds prolonged or PTA <60%;
  • serum albumin<32 g/L;
  • serum bilirubin>3.0mg/dL;
  • Hemoglobin<11g/dL(males) or <10 g/dL(females), white blood cells count<3.5 x 10^9/L, absolute neutrophil count <1.5 x 10^9/L, platelets<80 x 10^9/L.
• Patient is coinfected with HCV, HDV or HIV.
• Hepatocellular carcinoma (HCC), or the presence of a mass on imaging studies of the liver that is suggest of HCC, or an alpha-fetoprotein (AFP)> 500ng/mL.
• Decompensated liver disease as defined by serum bilirubin >3mg/dL, prothrombin time≥ 4 seconds prolonged, a serum albumin<32g/L, or a history of ascites, variceal bleeding or hepatic encephalopathy.
• Presence of other causes of liver disease (i.e.alcoholic liver disease,autoimmune hepatitis, hemochromatosis, Wilson disease, nonalcoholic steatohepatitis, alpha-1anti-trypsin deficiency).
• Any serious or active medical or psychiatric illnesses other than hepatitis B which, in the opinion of the investigator, would interfere with patient treatment, assessment or compliance with the protocol. This would include, may not limit to, renal, cardiac, pulmonary, vascular, neurogenic, digestive, metabolic (diabetes, thyroid disorders, adrenal disease), immunodeficiency disorders, active infection or cancer.
• BMI≥30.
• Patient is pregnant or breast-feeding.
• Planned for liver transplantation or previous liver transplantation.
• Need take hepatotoxic drugs (e.g.,dapsone, erythromycin, fluconazole, rifampin, etc) and nephrotoxic drugs (e.g., NSAIDs, aminoglycosides, amphotericin B, foscarnet, etc.) for long time.
• History of hypersensitivity to nucleoside analogues.
• Previous (or planned) participation in an investigational trial involving administration of investigational compound within 12 weeks prior to the study screening.
• Poor compliance of the patient considered by investigator.

• Sanofi
• Fujian Cosunter Pharmaceutical Co. Ltd